Caplin Point Laboratories Past Earnings Performance
Past criteria checks 3/6
Caplin Point Laboratories has been growing earnings at an average annual rate of 19%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 16.3% per year. Caplin Point Laboratories's return on equity is 19.3%, and it has net margins of 26.9%.
Key information
19.0%
Earnings growth rate
19.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.3% |
| Return on equity | 19.3% |
| Net Margin | 26.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking
Dec 01
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Revenue & Expenses Breakdown
How Caplin Point Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 18,328 | 4,936 | 1,580 | 737 |
| 30 Jun 24 | 17,577 | 4,776 | 1,487 | 0 |
| 31 Mar 24 | 16,961 | 4,571 | 1,437 | 737 |
| 31 Dec 23 | 16,318 | 4,376 | 1,430 | 632 |
| 30 Sep 23 | 15,683 | 4,179 | 1,408 | 632 |
| 30 Jun 23 | 15,157 | 3,947 | 1,396 | 0 |
| 31 Mar 23 | 14,683 | 3,763 | 1,371 | 632 |
| 31 Dec 22 | 14,182 | 3,532 | 1,314 | 593 |
| 30 Sep 22 | 13,724 | 3,307 | 1,262 | 593 |
| 30 Jun 22 | 13,153 | 3,140 | 1,210 | 0 |
| 31 Mar 22 | 12,710 | 2,998 | 1,154 | 593 |
| 31 Dec 21 | 12,099 | 2,872 | 1,110 | 537 |
| 30 Sep 21 | 11,581 | 2,767 | 1,071 | 537 |
| 30 Jun 21 | 11,217 | 2,586 | 1,034 | 0 |
| 31 Mar 21 | 10,624 | 2,423 | 1,026 | 537 |
| 31 Dec 20 | 9,986 | 2,248 | 952 | 530 |
| 30 Sep 20 | 9,524 | 2,189 | 874 | 530 |
| 30 Jun 20 | 9,107 | 2,193 | 780 | 0 |
| 31 Mar 20 | 8,640 | 2,150 | 678 | 530 |
| 31 Dec 19 | 8,356 | 2,159 | 617 | 282 |
| 30 Sep 19 | 7,664 | 2,032 | 557 | 282 |
| 30 Jun 19 | 6,948 | 1,894 | 512 | 0 |
| 31 Mar 19 | 6,490 | 1,766 | 471 | 282 |
| 31 Dec 18 | 6,048 | 1,621 | 449 | 237 |
| 30 Sep 18 | 5,874 | 1,538 | 431 | 237 |
| 30 Jun 18 | 5,628 | 1,459 | 417 | 0 |
| 31 Mar 18 | 5,399 | 1,448 | 391 | 237 |
| 31 Dec 17 | 5,145 | 1,430 | 367 | 141 |
| 30 Sep 17 | 4,757 | 1,297 | 352 | 141 |
| 30 Jun 17 | 4,401 | 1,165 | 322 | 0 |
| 31 Mar 17 | 4,016 | 956 | 321 | 141 |
| 31 Dec 16 | 3,655 | 783 | 300 | 54 |
| 30 Sep 16 | 3,420 | 703 | 274 | 54 |
| 30 Jun 16 | 3,238 | 619 | 258 | 54 |
| 31 Mar 16 | 3,088 | 584 | 240 | 54 |
| 31 Dec 15 | 2,906 | 535 | 298 | 67 |
| 30 Sep 15 | 2,722 | 465 | 283 | 60 |
| 30 Jun 15 | 2,518 | 410 | 203 | 59 |
| 31 Mar 15 | 2,296 | 353 | 233 | 53 |
| 31 Dec 14 | 2,074 | 318 | 220 | 42 |
| 30 Sep 14 | 1,893 | 305 | 204 | 33 |
| 30 Jun 14 | 1,731 | 258 | 190 | 21 |
| 31 Mar 14 | 1,643 | 204 | 166 | 4 |
| 31 Dec 13 | 1,517 | 167 | 149 | 0 |
Quality Earnings: CAPLIPOINT has high quality earnings.
Growing Profit Margin: CAPLIPOINT's current net profit margins (26.9%) are higher than last year (26.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAPLIPOINT's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: CAPLIPOINT's earnings growth over the past year (18.1%) is below its 5-year average (19% per year).
Earnings vs Industry: CAPLIPOINT earnings growth over the past year (18.1%) did not outperform the Pharmaceuticals industry 20.4%.
Return on Equity
High ROE: CAPLIPOINT's Return on Equity (19.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caplin Point Laboratories Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Siddhant Khandekar | ICICIdirect.com |